Summary
The emergence of antibiotic resistant bacteria by mutations or by acquisition of genetic material like resistance plasmids represents a major public health issue 1,2 (Extended Data Fig. 1a). Persisters are bacterial subpopulations surviving antibiotics by reversibly adapting their physiology 3–10. They promote the emergence of antibiotic resistant mutants 11. We asked if persisters can also promote the spread of resistance plasmids. In contrast to mutations, resistance plasmid transfer requires the co-occurrence of two different bacterial strains: a donor and a recipient (Extended Data Fig. 1a). For our experiments, we chose the facultative intracellular entero-pathogen Salmonella enterica serovar Typhimurium (S.Tm) and E. coli, a common microbiota member 12. S.Tm forms persisters surviving antibiotic therapy in several host tissues. We show that tissue-associated, S.Tm persisters account for long-lived reservoirs of plasmid donors or recipients. Persistent S.Tm reservoir formation requires Salmonella Pathogenicity Island (SPI) -1/2 in the gut-associated tissues or SPI-2 at systemic sites. Re-seeding of these bacteria into the gut lumen allows co-occurrence of donors with gut-resident recipients, thereby favouring plasmid transfer between various Enterobacteriaceae. We observe up to 99% transconjugants within 2-3 days after re-seeding. Mathematical modeling shows that rare re-seeding events may suffice for a high frequency of conjugation. Vaccination reduces tolerant reservoir formation after oral Salmonella infection and subsequent plasmid transfer. We conclude that even without selection for plasmid-encoded resistance genes, small persistent pathogen reservoirs can foster the spread of promiscuous resistance plasmids in the gut.
Salmonella enterica and E. coli strains harbor numerous resistance plasmids 13,14 and different strains frequently colonize the same host 15–19. High cell densities in the gut lumen allows high rates of plasmid transfer within and between species 20–22. S.Tm strains can colonize the gut lumen and survive within tissues of the host for prolonged periods of time 5–7,15–17,23. In the absence of suitable resistance genes, the gut luminal S.Tm population is eliminated by antibiotics within a few hours, while tissue-associated S.Tm persister cells survive >10 days 5–8,24 (supplementary discussion A). After antibiotic withdrawal, surviving cells can migrate to the gut lumen and resume growth 24. We hypothesized that this promotes co-occurrence of donors with gut-luminal recipients and thereby fuels resistance plasmid transfer in vivo.
Wild-type S.Tm SL1344, which naturally carries P2, served as the donor. P2 is a well-characterized conjugative plasmid in Enterobacteriaceae 20–22 of the IncI1 incompatibility group (Extended Data Fig. 1b) 25. We labeled P2 with a chloramphenicol resistance marker (P2cat) to monitor plasmid transfer by plating (Extended Data Fig. 1c-d). Controls excluded cross-resistance for any resistance markers used in this study (Extended Data Fig. 2). In the "oral model", the donor (S.Tm P2cat) initially colonized the gut lumen and invaded host tissues (Fig. 1a-b; Extended Data Fig. 3). Ciprofloxacin cleared the gut luminal bacteria, while tissue-associated S.Tm P2cat persisters survived 5–8. The recipient S.Tm ATCC 14028S (naturally lacking P2) was introduced at day 8 21,22. Transconjugants (recipients that obtained the plasmid) replaced the recipients within 1-3 days after donor re-seeding (>99% median; day 11-12 of experiment; Fig. 1C; Extended Data Fig. 3a). Control experiments refuted that the rise of the transconjugants is attributable to P2-mediated fitness benefits over the recipients (Extended Data Fig. 3d-e). Further controls verified that P2cat transfer occurs in the gut lumen (Extended Data Fig. 3f-g) and that P2cat spreads by conjugation (Extended Data Fig. 3h-i). Non-invasive donor mutants (S.Tmnoninv P2cat) indicated that donor cells originated from persistent tissue-associated S.Tm P2cat reservoirs (Fig. 1c-e; Extended Data Fig. 3b, 4). However, this cannot definitively rule out that rare persisters could also exist in the gut lumen.
To verify the importance of tissue-associated, persistent S.Tm reservoirs we employed an intravenous infection model (I.V. model; Fig. 2a-b). In line with previous work 23, S.Tm P2cat formed large populations of persisters surviving intraperitoneal ceftriaxone treatment in the spleen and the liver (Fig. 2c-d; Extended Data Fig. 5a). In contrast to the oral model, gut luminal colonization by S.Tm P2cat is observed only very rarely by day 5 (Extended Data Fig. 5). Nevertheless, when donors were detected in the gut lumen, transconjugants were formed with high efficiency within 1-3 days (Fig. 2e; Extended Data Fig. 5b). Donors lacking a key virulence factor promoting systemic pathogen growth in vivo 26 and the survival of persisters 27(S.TmSPI-2 P2cat), yielded much smaller persister reservoirs than wild type S.Tm P2cat (Fig. 2d) and failed to produce transconjugants (Fig. 2e; Extended Data Fig. 5c). We conclude that tissue-associated S.Tm persisters can serve as reservoirs promoting the spread of conjugative plasmids.
Next, we identified the rate-limiting process in transconjugant formation in vivo, focusing on the oral model. Three key parameters may dictate plasmid transfer dynamics: 1) re-seeding, i.e. the rate at which plasmid-carrying donors re-enter the gut lumen and perform the initial conjugation event (dependent on the persistent reservoir population), 2) the rate of plasmid transfer from transconjugants to recipients, and 3) the relative growth rate of transconjugants over recipients. To estimate these rates, we used donor-mixtures carrying five DNA-tagged P2cat variants (S.Tm P2cat TAG; Extended Data Fig. 6). While all tags were present at roughly equivalent abundance in the inoculum, the feces (day 1) and the mucosa (day 15), most transconjugant populations harbored just one or two of the five tags (Fig. 3a-b; Extended Data Fig. 6b-c). In the I.V. infection experimental setup (Fig. 2b, 2e), transconjugants were also dominated by only one tag (Extended Data Fig. 6d-f). Thus, transconjugant populations arise from very few donor-to-recipient conjugation events, followed by transconjugant-to-recipient spread.
To quantify the relative contribution of donor re-seeding and plasmid conjugation, we developed a mathematical model (Extended Data Fig. 6g). It assessed the interdependence of the donor-re-seeding rate (η, the sum of donor re-seeding plus the donor-to-recipient conjugation) and γ, the rate of transconjugant-to-recipient conjugation (see supplementary material). Fitting our mathematical model to the plasmid tag distributions confirmed that η is rate-limiting and identified the most likely parameters, i.e. η = 3.16×10-10 per day and γ = 3.16×10-8 per CFU/g feces per day (red in Fig. 3c; marginal posterior densities listed in Supplementary Table 4). This corresponds to ≈1.6 donor re-seeding (plus initial plasmid transfer) events per day into the gut lumen. In contrast, transconjugant-to-recipient plasmid conjugation rates were ≥32 per day (initial conjugations) and increase exponentially thereafter (see supplementary material).
We then employed our mathematical model to predict the effect of reducing the rate of donor re-seeding (η). The transconjugant-to-recipient conjugation parameter was fixed to γ = 3.16×10-8 per CFU/g feces per day (Fig. 3c), and we evaluated the probability of conjugation events to occur within the course of our 15-day experiment (Fig. 3d). Reducing η by more than 100-fold diminished conjugation (Fig. 3d). To test this prediction, we employed oral vaccination with killed S.Tm cells28, a procedure known to reduce S.Tm gut tissue invasion. In line with previous work 22, vaccinated mice contained 10-500 fold smaller persister reservoirs than naïve mice (Fig. 3e). Indeed, this prevented plasmid transfer in the vast majority of mice (Fig. 3f; Extended Data Fig. 7a-c). Moreover, the transconjugants detected in vaccinated mice appeared later than the transconjugants in non-vaccinated controls (Fig. 3f). Control experiments with reduced fractions of invasive donors verified this observation Extended Data Fig. 7d-g). Thus, the size of the tissue-associated persister reservoir is a main driver of the ensuing rise of transconjugants. These data confirm the predictions of our mathematical model (Fig. 3d) and suggest that vaccination might provide a means to prevent mucosa-associated conjugative plasmid reservoirs.
Next, we addressed if other microbiota strains could also acquire such plasmids. First, we analyzed P2cat transfer to the commensal E. coli strain 8178 20,22. For this purpose, we created an ampicillin resistant, P2-plasmid free derivative of E. coli 8178 20 and employed it as a recipient in the oral model (as in Fig. 1b). This yielded efficient plasmid transfer (Fig. 4a-b; Extended Data Fig. 8a). We tested if tissue-associated S.Tm persisters could also serve as the recipient. In the oral model (Fig. 1b), mice were first infected with a P2-cured variant of S.Tm SL1344 (KanR). Then, we treated with ciprofloxacin and ampicillin and introduced the donor (E. coli 8178 P2cat; AmpR; CmR). S.Tm re-seeded the gut lumen and transconjugants were formed (>38% median; Extended Data Fig. 8b-d). Thus, tissue-associated S.Tm persisters can serve as both donors or recipients of plasmid transfer between different Enterobacteriaceae.
To assess if mucosa-associated S.Tm can also serve as a reservoir for clinically relevant plasmids carrying extended spectrum beta-lactamase (ESBL) genes, we used pESBL15 (Extended Data Fig. 1b). S.Tm SL1344 pESBL15 was used as a donor. We modified our oral model from Fig. 1b in two ways: by replacing ampicillin with kanamycin in the drinking water and by using an ampicillin-sensitive, but kanamycin-resistant, variant of our standard recipient strain (S.Tm 14028S aphT (KanR, AmpS)). We observed tissue-associated persisters, re-seeding of the gut-lumen and efficient plasmid transfer (Fig. 4c-d; Extended Data Fig. 8e). Thus, our findings apply to clinically important resistance plasmids. The choice of the antibiotics used for the different phases of our oral model had little effect on these fast plasmid transfer kinetics (Extended Data Fig. 9a-d).
Finally, we validated transfer of antibiotic resistance plasmids to E. coli in the I.V. model. I.V. infection of S.Tm P2cat led to persistent populations in the internal organs (Fig. 4e) which migrated into the gut lumen and transferred the plasmid into the luminal recipient population, forming >25% E. coli transconjugants in the absence of antibiotic selection (Fig. 4f; Extended Data Fig. 9e). Thus, tissue-associated, S.Tm persisters can serve as reservoir for resistance plasmids that can be efficiently transferred to different Enterobacteriaceae.
Our results uncover a mechanism by which antibiotic persistence promotes the spread of antibiotic resistance plasmids, specifically by promoting the co-occurrence of donors and recipient bacteria in the gut luminal niche. This reveals an important new role of persistence in clinical bacterial infection: not only can bacterial persistence lead to relapse of disease in chronic infections, but it can also facilitate the spread of antibiotic resistance. In our case, the transfer rate is independent of selective pressures for functions encoded on the plasmid. Thus, in absence of antibiotic-driven selection, resistance genes on promiscuous plasmids can spread from a very small number of donor cells co-occurring with dense recipient cell populations.
Mathematical modelling showed that re-seeding is the rate limiting aspect of this process, and suggested that reducing the tissue-associated population of S.Tm (e.g., through vaccination) could reduce plasmid re-seeding to negligible levels. As re-seeding events are rare compared to the number of tissue-associated persisters, such persister-promoted plasmid spread may last for weeks or months after an acute infection. So far, we do not know if this translates to livestock or human infections, where tissue-associated persister reservoirs might be smaller.
Associations between persistence and chronic infections happen in various clinical contexts 29 and biofilms 30. Therefore, reservoirs for conjugative plasmids could exist in a multitude of persister populations. In our two mouse models, S.Tm persisters associated with different organs appear capable of gut-luminal re-seeding. The intracellular environment in classical dendritic cells 7 or macrophages 6 can induce persistence. In contrast to infected epithelial cells31,32, these phagocytes are long-lived, suggesting they hold most of the persistent donors in both, the oral and the I.V. model. The differences between location of persister cell reservoirs in the oral model (lamina propria and mLN) and the I.V. model (spleen, liver, and gall bladder) and the differential requirement for SPI-1 and -2 encoded virulence factors indicate that there are diverse mechanisms by which tissue-associated S.Tm persisters can establish a reservoir, survive, and ultimately re-seed the gut lumen to engage in plasmid transfer.
The link between persistence and plasmid-mediated evolution of antibiotic resistance may be particularly relevant in the farming industry where S. enterica has a high prevalence, and animals are often co-colonized by Salmonella and E. coli strains. There can be two different Salmonella strains within the same host, one within lymphoid tissues (e.g. mesenteric lymph nodes) and the other in the intestinal content 17. This is also in line with the isolation of Salmonella spp. from intestinal biopsies in swine with persistent subclinical Salmonella infections, indicating that pathogen persister reservoirs are common in the gut mucosa of these animals 15,16. Our results suggest that this may promote the spread of resistance plasmids in animal herds.
Strategies to reduce bacterial persistence are of general importance (reviewed in 33). This is relevant not only for the clinical treatment of infected individuals 29, but also to minimize the impact of persistence on the global evolution of antibiotic resistance via both resistance mutations 11 and resistance plasmid spread (this work). Inactivated vaccines such as the peracetic acid killed Salmonella cells used herein, should be easily and safely applicable 28. Our data show that vaccination efficiently prevents not only tissue invasion and disease, but also minimizes tolerant reservoirs and subsequent resistance (e.g. ESBL-encoding) plasmid spread (Fig. 3).
Materials and methods
Strains and plasmids used in this study
Supplementary table 1 contains all strains and plasmids used in this study. For cultivation of bacteria, lysogeny broth (LB) media containing the appropriate antibiotics (50 μg/ml streptomycin (AppliChem); 6 μg/ml chloramphenicol (AppliChem); 50 μg/ml kanamycin (AppliChem); 100 μg/ml ampicillin (AppliChem)) were used. In order to create P2cat TAG strains (using neutral genetic barcodes from 34) or gene deletion mutants (e.g. oriT::aphT on P2), the λ red system was used as described in 35. If desired, antibiotic resistance cassettes were removed using the temperature-inducible FLP recombinase encoded on pCP20 35. Mutations or sequence tags coupled to antibiotic resistance cassettes were transferred into the desired genetic background using transduction with P22 HT105/1 int-201 36. Primers used for strain construction or verification of genetic background are listed in Supplementary table 2.
In vitro plasmid transfer kinetics
Overnight cultures with appropriate antibiotics of donor (SL1344 P2cat) and recipient (14028S aphT) strains carrying pM975 to confer ampicillin resistance were subcultured 1:20 in LB without antibiotics and grown for 4 hours. Approximately 102 CFU of each were added (sequentially as 25 μl volumes) to 450 μl LB with 100 μg/ml ampicillin. Samples were incubated at 37°C mixing at 1000 rpm for 24 hours. Aliquots (10 μl) were taken every hour, diluted, and plated on selective MacConkey agar for enumeration.
In vitro antibiotic resistance profiling
Flat-bottom transparent 96-well plates were filled with 100 μl of LB containing 2-fold dilutions of the specified antibiotic (streptomycin (AppliChem), chloramphenicol (AppliChem), kanamycin (AppliChem), ampicillin (AppliChem), ciprofloxacin (ciprofloxacin hydrochloride monohydrate; Sigma-Aldrich), gentamycin (AppliChem), or ceftriaxone (ceftriaxone disodium salt hemi(heptahydrate); Sigma-Aldrich). Each plate contained 11 2-fold dilution steps of each antibiotic, plus a no antibiotic control, and a no-bacteria sterility control. Overnight cultures of each bacterial strain tested were grown in the presence of appropriate antibiotics, subcultured (1:20 dilution) for 4 hours at 37°C in LB without antibiotics, and diluted in PBS. Cells were seeded in each well at a final density of 105 CFU/ml. 96-well plates were incubated at 37°C at 120 rpm for 16 hours and the OD600nm was measured. The no-bacteria sterility control was used for background subtraction.
Infection experiments
Oral infection model
For in vivo plasmid transfer experiments, 8-12 week old 129Sv/Ev mice were used. These mice are Nramp1+/+ and therefore allow for long-term S.Tm infections 37. They carry a complex specified pathogen free microbiota without E. coli. The experiment has three phases, i.e., 1) donor colonization, 2) clearance with antibiotics, and 3) recipient colonization and conjugative transfer. Phase 1: Animals were pretreated with 25 mg streptomycin orally to allow for robust colonization of S.Tm 38. Donor (i.e., plasmid-bearing) S.Tm were cultivated overnight at 37°C in LB containing the appropriate antibiotics, subcultured (1:20 dilution) for 4 hours at 37°C in LB without antibiotics, washed with sterile PBS, and 5x107 CFU were introduced into mice via oral gavage 38. Phase 2: Two days post infection, 3 mg of ciprofloxacin (ciprofloxacin hydrochloride monohydrate; Sigma-Aldrich) dissolved in 100 μl sterile dH2O was administered by oral gavage for three consecutive days. Mice were transferred to fresh cages after each ciprofloxacin treatment to minimize gut recolonization from the environment. Ampicillin (2 g/l) or kanamycin (1 g/l) was added to the drinking water starting at day 3 post infection and maintained until either day 8 or day 15. This prevented premature donor re-seeding after the cessation of ciprofloxacin treatment. Phase 3: Mice were kept individually after ciprofloxacin treatment to prevent cross-contamination due to coprophagy. Recipient bacteria (i.e., plasmid-free S.Tm or E. coli; 5x107 CFU) were orally introduced into mice on day 8 post infection (culture and subculture conditions as above) and populations are monitored for 7 days until sacrifice (day 15).
I.V. infection model
The in vivo plasmid transfer experiment has three phases, i.e. 1) donor colonization, 2) clearance with antibiotics, and 3) recipient colonization and conjugative transfer. Phase 1: The donor strain is injected intravenously into the tail vein of 8-12 week old 129Sv/Ev mice (103 CFU). Phase 2: 2 days after I.V. infection of donors, 1.5 mg of ceftriaxone (ceftriaxone disodium salt hemi(heptahydrate); dissolved in 100 μl PBS; Sigma-Aldrich) was intraperitoneally injected for three consecutive days. After the third treatment, mice were transferred to fresh cages and kept individually to prevent cross-contamination due to coprophagy. Phase 3: the recipient is introduced on day 7 post donor infection (108 CFU by gavage) and fecal populations are monitored for 18 days until sacrifice (day 25).
In both infection models, feces were collected daily, homogenized in PBS with a steel ball at 25 Hz for 1 minute, diluted, and selective plating on MacConkey agar (supplemented with the appropriate antibiotics) was used to enumerate populations of donors, recipients, or transconjugants. The proportion of transconjugants was calculated by dividing the transconjugant population (CmR, KanR) by the sum of transconjugants and plasmid-free recipients (KanR). Lipocalin-2 ELISA (R&D Systems kit; protocol according to manufacturer) was performed on feces to determine the inflammatory state of the gut. Upon sacrifice (at day 5, 8, 15, or 25; specified in each figure legend), the mesenteric lymph nodes, spleen, liver, and gall bladder were collected, homogenized in PBT at 25 Hz for 2 minutes, and bacteria were enumerated by selective plating. The cecum was removed, opened longitudinally, washed 3 times in PBS, and then placed in 400 μg/ml gentamycin (AppliChem) for 30 minutes at room temperature. 9 consecutive washing steps in PBS (45 seconds each) ensured removal of gentamycin; cecal tissue was subsequently homogenized and mucosa-associated bacteria were enumerated as for the other organs (gentamycin protection protocol modified from 24). In Extended Data Fig. 5a, additional organs were collected as indicated in the figure legend. All organs were processed as indicated above. For the jejunum, ileum, and colon, 1 cm of intestine was harvested, washed briefly in PBS and the tissue (including the majority of the content) was analyzed. For analysis of bacteria in the blood, 100 μl of blood was aspirated from the heart immediately after sacrifice and mixed in PBS containing 2% BSA and 1 mM EDTA to prevent coagulation.
For competition experiments, 8-12 week old 129 SvEv mice were pretreated with 20 mg ampicillin orally, and ampicillin (2 g/l) was maintained in the drinking water throughout the experiment. The two competitor strains were cultured separately in LB containing the appropriate antibiotics, subcultured, and washed with PBS, as above. Strains were mixed at a 1:1 ratio immediately before gavaging 5x107 CFU of the mixture into the ampicillin pretreated mice. Feces were monitored daily, homogenized, and enumerated by selective plating. Competitive index was calculated by the ratio of population sizes of competitors at the indicated time. Mice were sacrificed after 7 days.
All animal infection experiments were approved by the responsible authority (Tierversuchskommission, Kantonales Veterinäramt Zürich, license 193/2016). Sample size was not predetermined. Mouse age and gender were matched between treatment groups and animals were randomly distributed among groups. In four cases, data from mice were excluded since the animals needed to be sacrificed prematurely due to disease or symptom severity.
Confocal microscopy
To visualize persisters in the cecum lamina propria, cecum tissues were fixed in PBS/4% paraformaldehyde, saturated in PBS/20% sucrose and embedded in optimum cutting temperature medium (OCT, Tissue-Tek) before being flash-frozen in liquid nitrogen. 10 μm cryosections were air-dried, rehydrated with PBS, permeabilized with PBS/0.5%Triton X-100 and blocked with PBS/10% Normal Goat Serum. α-S.Tm LPS O5 (Difco), α-S.Tm LPS O12 (STA5; 22), α-ICAM-1/CD54 (BD Biosciences), appropriate secondary antibodies, DAPI (Sigma Aldrich) and AlexaFluor488-conjugated phalloidin (Santa Cruz) were used for the staining. A Zeiss Axiovert 200m microscope with 10x–100x objectives, a spinning disc confocal laser unit (Visitron), and two Evolve 512 EMCCD cameras (Photometrics) were used for acquiring images. Images were processed using Visiview (Visitron). LPS positive (O5-positive and/or O12-positive) S.Tm were manually enumerated blindly in 8-12 nonconsecutive sections per mouse. Phalloidin and ICAM-1 staining were used to differentiate the lamina propria and epithelium. All data represent averages per section.
Mucus fixation and staining
Cecal tissue samples were fixed with freshly prepared Methacarn solution (60% methanol, 30% chloroform, 10 % glacial acetic acid) for 24 hours at room temperature 39. The samples were transferred to methanol for 2 hours and processed over night with a LogosJ tissue processor (Milestone) using the following program:
30 min | 37°C EtOH | |
30 min | 37°C EtOH | |
60 min | 37°C EtOH | |
60 min | 40°C Isopropanol | 15 min for heating up |
60 min | 45°C Isopropanol | 20 min for heating up |
180 min | 68°C Isopropanol | 20 min for heating up |
240 min | 82°C Paraffin | 75 min for heating up |
The paraffinized tissue was then embedded as paraffin blocks for further storage. 10 μm sections were deparaffinized in Xylene substitute solution (Sigma-Aldrich) for 20 minutes. The sections were rehydrated in sequential baths of 100%, 95%, 70%, 50% and 30% ethanol for 5 minutes each and subsequently incubated for 10 min in PBS. For mucus visualization, the sections were stained with DAPI, phalloidin-FITC, Wheat germ agglutinin (WGA) AF647 conjugate (Invotrogen, Cat#W32466), Rabbit polyclonal anti-Salmonella O5 (Becton Dickinson, Cat#226601) and Goat polyclonal anti-Rabbit Fab Cy3 conjugate (Jackson ImmunoResearch Labs, Cat# 111-167-003; RRID: AB_2313593) antibodies.
Analysis of plasmid transfer dynamics
Mice were orally or I.V. infected with a mixture of 5 isogenic SL1344 P2cat TAG strains (tags at a 1:1:1:1:1 ratio; inoculum made of approximately 107 CFU each tagged strains for oral infection and 2×102 CFU each tagged strain for I.V. infection) using the same oral model or I.V. model protocol described above (Fig. 1b, 2b). On day 8 (oral model), mice were gavaged with a mixture of 5 recipient strains (14028S TAG; KanR; AmpR; tags at 1:1:1:1:1 ratio; inoculum approximately 107 CFU each tag). Barcode analysis of the recipient chromosome tags could not be performed for technical issues with kanamycin enrichments and subsequent qPCR. In the I.V. model, the recipient used was not tagged, but was introduced on day 7 (108 CFU by oral gavage). The plasmid and recipient tags can be easily distinguished since the primer pairs used for qPCR are unique (i.e., WITSX-R paired with Cat_internal for P2 tags; WITSX-R paired with Kan_internal for recipient tags; in the IV model where recipient tags were not used, WITSX was paired with ydgA for qPCR as there was no need for antibiotic resistance-specific qPCR primers). For the oral model, the inoculums, feces at day 1, 9, and 15, as well as cecal tissue after gentamycin treatment was enriched overnight in 5 ml LB containing the appropriate antibiotics (donors = Sm+Cm; recipients = Kan; transconjugants = Cm+Kan) in parallel to selective plating to enumerate bacterial population sizes. For the I.V. model, the donor inoculum, as well as feces, gall bladder, liver, spleen, mLN, and cecal tissue at sacrifice (day 25) were enriched in LB with the appropriate antibiotics.
Enrichments were concentrated and genomic DNA was extracted using a QIAamp DNA Mini Kit (Qiagen). qPCR analysis was performed using temperature conditions described previously 34. qPCR primers are listed in Supplementary table 2. For each sample, 5 primer pairs were used to amplify P2 tags (in the oral model WITSX-R with Cat_internal, where X is 2, 11, 13, 19, or 21; in the IV model WITSX with ydgA where X is 2, 11, 13, 19, or 21). Primers were modified from the original WITS primers described in 34; tag loci remain the same as in 34. Relative proportion was determined by dividing the DNA copy number (calculated from the CT value; a dilution standard of purified chromosomal DNA allowed for a correlation between DNA copy number and CT value) of each tag detected by the sum of all tags in the sample. The detection limit was determined by the CT value of the most diluted DNA standard (linearity of the standard curve decreases dramatically below this value) for each qPCR run. The least precise detection limit constitutes the conservative detection limit used for fitting our mathematical model (2.9×10-3). Plasmid tags were ranked according to frequency (Extended Data Fig. 6c) as the strains are isogenic (except for the tag), and each mouse can be treated as an independent realization of the stochastic population dynamics. The data of plasmid tag frequencies and the bacterial population counts were used to parametrize a mechanistic model of the plasmid re-seeding dynamics, and infer the most likely rates of donor re-seeding (including initial plasmid transfer) and transconjugant-to-recipient transfer (Extended Data Fig. 6g; a detailed description is given in the supplementary materials).
Oral vaccination
Peracetic acid inactivated oral vaccines were prepared as described previously 28. S.Tm was grown overnight and concentrated to 1010 CFU/ml in PBS. Peracetic acid (Sigma-Aldrich) was added to a final concentration of 0.4% v/v, mixed vigorously, and incubated at room temperature for 2 hours. Traces of acid were removed after inactivation by washing bacteria with sterile PBS three times. Inactivated bacteria were resuspended at 1011 particles per ml in sterile PBS. Complete inactivation was ensured by inoculating a 100 μl dose of vaccine into 50 ml LB and checking for sterility. Vaccines were stored at 4°C for up to 2 months. Mice received a 100 μl dose of vaccine by oral gavage once per week for 5 weeks. Naïve control mice were mock-vaccinated with PBS.
Statistical analysis
Statistical tests on experimental data were performed using GraphPad Prism 7 for Windows. Fitting of the mathematical model to experimental values was performed using an Approximate Bayesian Computation (ABC) approach 40. Transfer rates were varied on a grid from 10-12 – 10-1; the summary statistics consist of the skew of the plasmid tag abundance distribution, the fraction of tags above the detection limit on day 15, the total size of the transconjugant population on day 15, as well as the time at which the transconjugant population size first exceeds 106 CFU/g feces. A simulation is called “successful” if all summary statistics are within three standard deviations of the experimentally observed mean of these statistics. All R-code needed to simulate the stochastic model, estimate the most likely parameters from the experimental data, and plot the results, is included in the attached zip-folder.
Extended Data
Supplementary Material
Acknowledgements
We would like to extend our gratitude to the members of the Hardt, Slack, Bonhoeffer, Stadler, and Ackermann labs for helpful discussion, and to the staff at the RCHCI and EPIC animal facilities for their excellent support. This work has been funded in part by grants from the Swiss National Science Foundation (SNF; 310030B-173338), the Promedica Foundation, Chur and the Helmut Horten Foundation to WDH, and from the SNF (407240-167121) to WDH, SB, and AE. MD is funded by an SNF professorship grant (PP00PP_176954), EB by a Boehringer Ingelheim Fonds PhD fellowship, and MES and partly SAF by the Swedish Research Council (2015-00635, 2018-02223). RRR is funded by SNF grant number 31003A_149769. ES is supported by grant GRS 073/17 from the"Microbials" programme of the Gebert Rüf Foundation and the SNF Bridge Discover Grant 20B2-1 180953. The authors declare no conflict of interest, financial or otherwise.
Footnotes
Data availability statement:
The genome and plasmid sequence of E. coli ESBL 15 were deposited in GenBank under accession numbers CP041678-CP041681 (Biosample SAMN12275742). Numerical source data for all figures are provided with the paper. Source images are available upon request to the corresponding authors.
Code availability statement:
Code for the stochastic simulation of plasmid transfer dynamics and parameter estimation from the experimental data is provided with the paper. All R-code needed to simulate the stochastic model, estimate the most likely parameters from the experimental data, and plot the results, is included in a zip-folder.
Ethical statement:
All animal experiments were ethically approved by the responsible authorities (Tierversuchskommission, Kantonales Veterinäramt Zürich, license 193/2016). In four cases, data from mice were excluded since the animals needed to be sacrificed prematurely due to disease or symptom severity.
Contributions:
EB (figures 1, 2, 3a-b, 3e-f, 4, ED1-3, ED4a-c, e-f, ED5-9), SAF (figures 1E, ED4a-d), AH (figures 2, ED5, ED6e-f, ED9e), MF (figure ED4e-h), ES (figures 3E-F, ED7b) performed the experiments. JSH, SB and RRR (figures 3C-D, ED1b, ED6g, ED10) performed mathematical modeling. AE (figure ED1b) provided E. coli strain Z2115. EB, MD and WDH designed the experiments. SAF, MF, and MES designed the microscopy-based experiments and analysis. EB, MD, and WDH conceived the project and wrote the manuscript. All authors read, commented, and approved this manuscript.
Competing interests
The authors declare no competing financial interests.
References
- 1.Parisi A, et al. Health Outcomes from Multidrug-Resistant Salmonella Infections in High-Income Countries: A Systematic Review and Meta-Analysis. Foodborne Pathog Dis. 2018 doi: 10.1089/fpd.2017.2403. [DOI] [PubMed] [Google Scholar]
- 2.Wright GD. The antibiotic resistome: the nexus of chemical and genetic diversity. Nat Rev Microbiol. 2007;5:175–186. doi: 10.1038/nrmicro1614. [DOI] [PubMed] [Google Scholar]
- 3.Brauner A, Fridman O, Gefen O, Balaban NQ. Distinguishing between resistance, tolerance and persistence to antibiotic treatment. Nat Rev Microbiol. 2016;14:320–330. doi: 10.1038/nrmicro.2016.34. [DOI] [PubMed] [Google Scholar]
- 4.Fridman O, Goldberg A, Ronin I, Shoresh N, Balaban NQ. Optimization of lag time underlies antibiotic tolerance in evolved bacterial populations. Nature. 2014;513:418–421. doi: 10.1038/nature13469. [DOI] [PubMed] [Google Scholar]
- 5.Claudi B, et al. Phenotypic variation of Salmonella in host tissues delays eradication by antimicrobial chemotherapy. Cell. 2014;158:722–733. doi: 10.1016/j.cell.2014.06.045. [DOI] [PubMed] [Google Scholar]
- 6.Helaine S, et al. Internalization of Salmonella by macrophages induces formation of nonreplicating persisters. Science. 2014;343:204–208. doi: 10.1126/science.1244705. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Kaiser P, et al. Cecum lymph node dendritic cells harbor slow-growing bacteria phenotypically tolerant to antibiotic treatment. PLoS Biol. 2014;12:e1001793. doi: 10.1371/journal.pbio.1001793. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 8.Dolowschiak T, et al. IFN-gamma Hinders Recovery from Mucosal Inflammation during Antibiotic Therapy for Salmonella Gut Infection. Cell Host Microbe. 2016;20:238–249. doi: 10.1016/j.chom.2016.06.008. [DOI] [PubMed] [Google Scholar]
- 9.Balaban NQ, et al. Definitions and guidelines for research on antibiotic persistence. Nat Rev Microbiol. 2019 doi: 10.1038/s41579-019-0196-3. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Balaban NQ, Merrin J, Chait R, Kowalik L, Leibler S. Bacterial persistence as a phenotypic switch. Science. 2004;305:1622–1625. doi: 10.1126/science.1099390. [DOI] [PubMed] [Google Scholar]
- 11.Levin-Reisman I, et al. Antibiotic tolerance facilitates the evolution of resistance. Science. 2017;355:826–830. doi: 10.1126/science.aaj2191. [DOI] [PubMed] [Google Scholar]
- 12.Wotzka SY, et al. Microbiota stability in healthy individuals after single-dose lactulose challenge-A randomized controlled study. PLoS One. 2018;13:e0206214. doi: 10.1371/journal.pone.0206214. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 13.Coque TM, Baquero F, Canton R. Increasing prevalence of ESBL-producing Enterobacteriaceae in Europe. Euro Surveill. 2008;13 [PubMed] [Google Scholar]
- 14.Crump JA, Sjolund-Karlsson M, Gordon MA, Parry CM. Epidemiology, Clinical Presentation, Laboratory Diagnosis, Antimicrobial Resistance, and Antimicrobial Management of Invasive Salmonella Infections. Clin Microbiol Rev. 2015;28:901–937. doi: 10.1128/CMR.00002-15. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Wilcock BP, Armstrong CH, Olander HJ. The significance of the serotype in the clinical and pathological features of naturally occurring porcine salmonellosis. Can J Comp Med. 1976;40:80–88. [PMC free article] [PubMed] [Google Scholar]
- 16.Wood RL, Pospischil A, Rose R. Distribution of persistent Salmonella typhimurium infection in internal organs of swine. Am J Vet Res. 1989;50:1015–1021. [PubMed] [Google Scholar]
- 17.San Roman B, et al. Relationship between Salmonella infection, shedding and serology in fattening pigs in low-moderate prevalence areas. Zoonoses Public Health. 2018 doi: 10.1111/zph.12453. [DOI] [PubMed] [Google Scholar]
- 18.Tenaillon O, Skurnik D, Picard B, Denamur E. The population genetics of commensal Escherichia coli. Nat Rev Microbiol. 2010;8:207–217. doi: 10.1038/nrmicro2298. [DOI] [PubMed] [Google Scholar]
- 19.Apperloo-Renkema HZ, Van der Waaij BD, Van der Waaij D. Determination of colonization resistance of the digestive tract by biotyping of Enterobacteriaceae. Epidemiol Infect. 1990;105:355–361. doi: 10.1017/s0950268800047944. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Stecher B, et al. Gut inflammation can boost horizontal gene transfer between pathogenic and commensal Enterobacteriaceae. Proc Natl Acad Sci U S A. 2012;109:1269–1274. doi: 10.1073/pnas.1113246109. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Diard M, et al. Inflammation boosts bacteriophage transfer between Salmonella spp. Science. 2017;355:1211–1215. doi: 10.1126/science.aaf8451. [DOI] [PubMed] [Google Scholar]
- 22.Moor K, et al. High-avidity IgA protects the intestine by enchaining growing bacteria. Nature. 2017 doi: 10.1038/nature22058. [DOI] [PubMed] [Google Scholar]
- 23.Monack DM, Bouley DM, Falkow S. Salmonella typhimurium persists within macrophages in the mesenteric lymph nodes of chronically infected Nramp1+/+ mice and can be reactivated by IFNgamma neutralization. J Exp Med. 2004;199:231–241. doi: 10.1084/jem.20031319. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Diard M, et al. Antibiotic treatment selects for cooperative virulence of Salmonella typhimurium. Curr Biol. 2014;24:2000–2005. doi: 10.1016/j.cub.2014.07.028. [DOI] [PubMed] [Google Scholar]
- 25.Sampei G, et al. Complete genome sequence of the incompatibility group I1 plasmid R64. Plasmid. 2010;64:92–103. doi: 10.1016/j.plasmid.2010.05.005. [DOI] [PubMed] [Google Scholar]
- 26.Hensel M, et al. Simultaneous identification of bacterial virulence genes by negative selection. Science. 1995;269:400–403. doi: 10.1126/science.7618105. [DOI] [PubMed] [Google Scholar]
- 27.Stapels DAC, et al. Salmonella persisters undermine host immune defenses during antibiotic treatment. Science. 2018;362:1156–1160. doi: 10.1126/science.aat7148. [DOI] [PubMed] [Google Scholar]
- 28.Moor K, et al. Peracetic Acid Treatment Generates Potent Inactivated Oral Vaccines from a Broad Range of Culturable Bacterial Species. Front Immunol. 2016;7:34. doi: 10.3389/fimmu.2016.00034. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 29.Fauvart M, De Groote VN, Michiels J. Role of persister cells in chronic infections: clinical relevance and perspectives on anti-persister therapies. J Med Microbiol. 2011;60:699–709. doi: 10.1099/jmm.0.030932-0. [DOI] [PubMed] [Google Scholar]
- 30.Roberts ME, Stewart PS. Modelling protection from antimicrobial agents in biofilms through the formation of persister cells. Microbiology. 2005;151:75–80. doi: 10.1099/mic.0.27385-0. [DOI] [PubMed] [Google Scholar]
- 31.Knodler LA, et al. Noncanonical inflammasome activation of caspase-4/caspase-11 mediates epithelial defenses against enteric bacterial pathogens. Cell Host Microbe. 2014;16:249–256. doi: 10.1016/j.chom.2014.07.002. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Sellin ME, et al. Epithelium-intrinsic NAIP/NLRC4 inflammasome drives infected enterocyte expulsion to restrict Salmonella replication in the intestinal mucosa. Cell Host Microbe. 2014;16:237–248. doi: 10.1016/j.chom.2014.07.001. [DOI] [PubMed] [Google Scholar]
- 33.Defraine V, Fauvart M, Michiels J. Fighting bacterial persistence: Current and emerging anti-persister strategies and therapeutics. Drug Resist Updat. 2018;38:12–26. doi: 10.1016/j.drup.2018.03.002. [DOI] [PubMed] [Google Scholar]
- 34.Grant AJ, et al. Modelling within-host spatiotemporal dynamics of invasive bacterial disease. PLoS Biol. 2008;6:e74. doi: 10.1371/journal.pbio.0060074. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Datsenko KA, Wanner BL. One-step inactivation of chromosomal genes in Escherichia coli K-12 using PCR products. Proc Natl Acad Sci U S A. 2000;97:6640–6645. doi: 10.1073/pnas.120163297. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 36.Sternberg NL, Maurer R. Bacteriophage-mediated generalized transduction in Escherichia coli and Salmonella typhimurium. Methods Enzymol. 1991;204:18–43. doi: 10.1016/0076-6879(91)04004-8. [DOI] [PubMed] [Google Scholar]
- 37.Stecher B, et al. Chronic Salmonella enterica serovar Typhimurium-induced colitis and cholangitis in streptomycin-pretreated Nramp1+/+ mice. Infect Immun. 2006;74:5047–5057. doi: 10.1128/IAI.00072-06. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 38.Barthel M, et al. Pretreatment of mice with streptomycin provides a Salmonella enterica serovar Typhimurium colitis model that allows analysis of both pathogen and host. Infect Immun. 2003;71:2839–2858. doi: 10.1128/IAI.71.5.2839-2858.2003. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 39.Johansson ME, Hansson GC. Preservation of mucus in histological sections, immunostaining of mucins in fixed tissue, and localization of bacteria with FISH. Methods Mol Biol. 2012;842:229–235. doi: 10.1007/978-1-61779-513-8_13. [DOI] [PubMed] [Google Scholar]
- 40.Marjoram P, Molitor J, Plagnol V, Tavare S. Markov chain Monte Carlo without likelihoods. Proc Natl Acad Sci U S A. 2003;100:15324–15328. doi: 10.1073/pnas.0306899100. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41.Zankari E, et al. Identification of acquired antimicrobial resistance genes. J Antimicrob Chemother. 2012;67:2640–2644. doi: 10.1093/jac/dks261. [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.